What is a stock summary page? Click here for an overview.
Business Description
Immunome Inc
NAICS : 541714
SIC : 2833
ISIN : US45257U1088
Share Class Description:
IMNM: Ordinary SharesCompare
Compare
Traded in other countries / regions
IMNM.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2020-10-02Description
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 44.97 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 1.28 | |||||
| Beneish M-Score | 0.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.8 | |||||
| 3-Year EPS without NRI Growth Rate | -3.9 | |||||
| 3-Year FCF Growth Rate | -20.9 | |||||
| 3-Year Book Growth Rate | -10.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 125.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.46 | |||||
| 9-Day RSI | 34.91 | |||||
| 14-Day RSI | 37.57 | |||||
| 3-1 Month Momentum % | -15.15 | |||||
| 6-1 Month Momentum % | -36 | |||||
| 12-1 Month Momentum % | -61.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.08 | |||||
| Quick Ratio | 4.08 | |||||
| Cash Ratio | 4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -74.6 | |||||
| Shareholder Yield % | -34.45 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1697.33 | |||||
| Net Margin % | -3240.38 | |||||
| FCF Margin % | -1817.3 | |||||
| ROE % | -138.8 | |||||
| ROA % | -116.1 | |||||
| ROIC % | -579.34 | |||||
| 3-Year ROIIC % | -441.78 | |||||
| ROC (Joel Greenblatt) % | -1828.29 | |||||
| ROCE % | -71.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 55.26 | |||||
| PB Ratio | 2.9 | |||||
| Price-to-Tangible-Book | 2.9 | |||||
| EV-to-EBIT | -3.25 | |||||
| EV-to-EBITDA | -3.3 | |||||
| EV-to-Revenue | 55.17 | |||||
| EV-to-FCF | -3.29 | |||||
| Price-to-Net-Current-Asset-Value | 3.23 | |||||
| Price-to-Net-Cash | 3.33 | |||||
| Earnings Yield (Greenblatt) % | -30.77 | |||||
| FCF Yield % | -23.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunome Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.041 | ||
| EPS (TTM) ($) | -5.17 | ||
| Beta | 3.02 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.17 | ||
| Volatility % | 67.15 | ||
| 14-Day RSI | 37.57 | ||
| 14-Day ATR ($) | 0.641606 | ||
| 20-Day SMA ($) | 8.999 | ||
| 12-1 Month Momentum % | -61.55 | ||
| 52-Week Range ($) | 8.12 - 26.7 | ||
| Shares Outstanding (Mil) | 86.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunome Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunome Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immunome Inc Frequently Asked Questions
What is Immunome Inc(IMNM)'s stock price today?
The current price of IMNM is $8.15. The 52 week high of IMNM is $26.70 and 52 week low is $8.12.
When is next earnings date of Immunome Inc(IMNM)?
The next earnings date of Immunome Inc(IMNM) is 2025-05-14 Est..
Does Immunome Inc(IMNM) pay dividends? If so, how much?
Immunome Inc(IMNM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers